Annual EBITDA
-$12.36 M
+$10.22 M+45.26%
December 31, 2023
Summary
- As of February 7, 2025, FENC annual EBITDA is -$12.36 million, with the most recent change of +$10.22 million (+45.26%) on December 31, 2023.
- During the last 3 years, FENC annual EBITDA has risen by +$5.74 million (+31.69%).
- FENC annual EBITDA is now -363.91% below its all-time high of $4.68 million, reached on December 31, 2011.
Performance
FENC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$4.68 M
-$202.00 K-4.51%
September 30, 2024
Summary
- As of February 7, 2025, FENC quarterly EBITDA is -$4.68 million, with the most recent change of -$202.00 thousand (-4.51%) on September 30, 2024.
- Over the past year, FENC quarterly EBITDA has dropped by -$202.00 thousand (-4.51%).
- FENC quarterly EBITDA is now -132.10% below its all-time high of $14.59 million, reached on March 31, 2024.
Performance
FENC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$3.73 M
-$3.75 M-50.11%
September 30, 2024
Summary
- As of February 7, 2025, FENC TTM EBITDA is $3.73 million, with the most recent change of -$3.75 million (-50.11%) on September 30, 2024.
- Over the past year, FENC TTM EBITDA has dropped by -$3.75 million (-50.11%).
- FENC TTM EBITDA is now -56.49% below its all-time high of $8.57 million, reached on September 30, 2012.
Performance
FENC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
FENC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +45.3% | -4.5% | -50.1% |
| 3 y3 years | +31.7% | +9.6% | +115.4% |
| 5 y5 years | -18.8% | +9.6% | +115.4% |
FENC EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +45.3% | -132.1% | +40.7% | -50.1% | +115.4% |
| 5 y | 5-year | at high | +45.3% | -132.1% | +40.7% | -50.1% | +115.4% |
| alltime | all time | -363.9% | +45.3% | -132.1% | +40.7% | -56.5% | +115.4% |
Fennec Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.68 M(+4.5%) | $3.73 M(-50.1%) |
| Jun 2024 | - | -$4.48 M(-130.7%) | $7.47 M(+1.9%) |
| Mar 2024 | - | $14.59 M(-960.0%) | $7.34 M(-159.0%) |
| Dec 2023 | -$12.36 M(-45.3%) | -$1.70 M(+80.7%) | -$12.44 M(-25.9%) |
| Sep 2023 | - | -$939.00 K(-79.7%) | -$16.78 M(-29.3%) |
| Jun 2023 | - | -$4.62 M(-10.9%) | -$23.75 M(-1.6%) |
| Mar 2023 | - | -$5.18 M(-14.2%) | -$24.15 M(+6.9%) |
| Dec 2022 | -$22.59 M(+31.2%) | -$6.04 M(-23.6%) | -$22.59 M(+8.0%) |
| Sep 2022 | - | -$7.91 M(+57.6%) | -$20.92 M(+22.0%) |
| Jun 2022 | - | -$5.01 M(+38.1%) | -$17.14 M(+6.3%) |
| Mar 2022 | - | -$3.63 M(-16.8%) | -$16.12 M(-6.4%) |
| Dec 2021 | -$17.22 M(-4.9%) | -$4.37 M(+5.7%) | -$17.22 M(+7.1%) |
| Sep 2021 | - | -$4.13 M(+3.5%) | -$16.08 M(-11.4%) |
| Jun 2021 | - | -$3.99 M(-15.6%) | -$18.15 M(-4.5%) |
| Mar 2021 | - | -$4.73 M(+46.5%) | -$19.00 M(+4.9%) |
| Dec 2020 | -$18.10 M(+39.1%) | -$3.23 M(-47.9%) | -$18.11 M(-2.3%) |
| Sep 2020 | - | -$6.20 M(+28.0%) | -$18.53 M(+30.6%) |
| Jun 2020 | - | -$4.84 M(+26.3%) | -$14.20 M(+0.2%) |
| Mar 2020 | - | -$3.83 M(+5.0%) | -$14.16 M(+8.9%) |
| Dec 2019 | -$13.01 M(+25.0%) | -$3.65 M(+96.1%) | -$13.01 M(+4.4%) |
| Sep 2019 | - | -$1.86 M(-61.3%) | -$12.46 M(-7.3%) |
| Jun 2019 | - | -$4.81 M(+79.6%) | -$13.45 M(+19.8%) |
| Mar 2019 | - | -$2.68 M(-13.7%) | -$11.22 M(+11.0%) |
| Dec 2018 | -$10.41 M(+49.7%) | -$3.10 M(+9.0%) | -$10.11 M(+6.2%) |
| Sep 2018 | - | -$2.85 M(+10.1%) | -$9.52 M(+7.5%) |
| Jun 2018 | - | -$2.59 M(+65.0%) | -$8.86 M(+14.3%) |
| Mar 2018 | - | -$1.57 M(-37.7%) | -$7.75 M(+11.5%) |
| Dec 2017 | -$6.95 M(+142.1%) | -$2.52 M(+15.1%) | -$6.95 M(+24.5%) |
| Sep 2017 | - | -$2.19 M(+47.8%) | -$5.58 M(+41.0%) |
| Jun 2017 | - | -$1.48 M(+91.8%) | -$3.96 M(+24.2%) |
| Mar 2017 | - | -$771.00 K(-32.7%) | -$3.19 M(+11.0%) |
| Dec 2016 | -$2.87 M(+51.9%) | -$1.15 M(+103.2%) | -$2.87 M(+26.1%) |
| Sep 2016 | - | -$564.00 K(-20.2%) | -$2.28 M(+11.0%) |
| Jun 2016 | - | -$707.00 K(+55.7%) | -$2.05 M(+8.4%) |
| Mar 2016 | - | -$454.00 K(-17.6%) | -$1.89 M(+0.1%) |
| Dec 2015 | -$1.89 M(-34.3%) | -$551.00 K(+63.0%) | -$1.89 M(-11.3%) |
| Sep 2015 | - | -$338.00 K(-38.4%) | -$2.13 M(-11.7%) |
| Jun 2015 | - | -$549.00 K(+21.5%) | -$2.41 M(-13.6%) |
| Mar 2015 | - | -$452.00 K(-42.9%) | -$2.79 M(-3.0%) |
| Dec 2014 | -$2.88 M(+49.0%) | -$791.00 K(+27.8%) | -$2.88 M(-39.4%) |
| Sep 2014 | - | -$619.00 K(-33.4%) | -$4.75 M(-19.4%) |
| Jun 2014 | - | -$930.00 K(+73.2%) | -$5.90 M(+0.1%) |
| Mar 2014 | - | -$537.00 K(-79.8%) | -$5.89 M(0.0%) |
| Dec 2013 | -$1.93 M(-62.6%) | -$2.67 M(+50.9%) | -$5.89 M(-39.5%) |
| Sep 2013 | - | -$1.77 M(+90.5%) | -$9.74 M(+11.5%) |
| Jun 2013 | - | -$927.00 K(+72.6%) | -$8.74 M(+3.9%) |
| Mar 2013 | - | -$537.00 K(-91.8%) | -$8.41 M(+63.0%) |
| Dec 2012 | -$5.16 M | -$6.51 M(+752.2%) | -$5.16 M(-160.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | -$764.00 K(+26.9%) | $8.57 M(+2.1%) |
| Jun 2012 | - | -$602.00 K(-122.2%) | $8.39 M(-0.4%) |
| Mar 2012 | - | $2.71 M(-62.4%) | $8.42 M(+79.8%) |
| Dec 2011 | $4.68 M(-159.9%) | $7.22 M(-864.9%) | $4.68 M(-171.3%) |
| Sep 2011 | - | -$944.00 K(+65.0%) | -$6.57 M(+0.4%) |
| Jun 2011 | - | -$572.00 K(-44.0%) | -$6.54 M(-23.4%) |
| Mar 2011 | - | -$1.02 M(-74.7%) | -$8.54 M(+8.3%) |
| Dec 2010 | -$7.82 M(+176.4%) | -$4.04 M(+340.0%) | -$7.89 M(+134.2%) |
| Sep 2010 | - | -$917.00 K(-64.3%) | -$3.37 M(+33.4%) |
| Jun 2010 | - | -$2.57 M(+601.9%) | -$2.52 M(+175.5%) |
| Mar 2010 | - | -$366.00 K(-175.5%) | -$916.00 K(-63.4%) |
| Dec 2009 | -$2.83 M(-79.4%) | $485.00 K(-755.4%) | -$2.50 M(-55.3%) |
| Sep 2009 | - | -$74.00 K(-92.3%) | -$5.60 M(-36.4%) |
| Jun 2009 | - | -$961.00 K(-50.8%) | -$8.81 M(-22.1%) |
| Mar 2009 | - | -$1.95 M(-25.4%) | -$11.31 M(-17.5%) |
| Dec 2008 | -$13.72 M(-2.0%) | -$2.62 M(-20.4%) | -$13.72 M(-3.8%) |
| Sep 2008 | - | -$3.29 M(-5.1%) | -$14.27 M(-0.8%) |
| Jun 2008 | - | -$3.46 M(-20.6%) | -$14.38 M(+0.6%) |
| Mar 2008 | - | -$4.36 M(+38.0%) | -$14.30 M(+2.2%) |
| Dec 2007 | -$14.00 M(-15.9%) | -$3.16 M(-7.1%) | -$14.00 M(-10.3%) |
| Sep 2007 | - | -$3.40 M(+0.6%) | -$15.61 M(-7.7%) |
| Jun 2007 | - | -$3.38 M(-16.7%) | -$16.91 M(-3.1%) |
| Mar 2007 | - | -$4.06 M(-15.0%) | -$17.45 M(+4.9%) |
| Dec 2006 | -$16.64 M(+8.8%) | -$4.77 M(+1.6%) | -$16.64 M(+2.1%) |
| Sep 2006 | - | -$4.70 M(+19.9%) | -$16.29 M(+4.3%) |
| Jun 2006 | - | -$3.92 M(+20.7%) | -$15.63 M(-1.7%) |
| Mar 2006 | - | -$3.25 M(-26.7%) | -$15.89 M(+3.9%) |
| Dec 2005 | -$15.29 M(+126.8%) | -$4.43 M(+9.8%) | -$15.29 M(+40.8%) |
| Sep 2005 | - | -$4.03 M(-3.6%) | -$10.86 M(+16.2%) |
| Jun 2005 | - | -$4.18 M(+58.0%) | -$9.35 M(+27.7%) |
| Mar 2005 | - | -$2.65 M(+5.1%) | -$7.32 M(-10.8%) |
| Sep 2004 | - | -$2.52 M(+16.8%) | -$8.21 M(+22.0%) |
| Jun 2004 | -$6.74 M(+33.6%) | -$2.16 M(+5.9%) | -$6.73 M(+10.5%) |
| Mar 2004 | - | -$2.04 M(+35.7%) | -$6.09 M(+13.7%) |
| Dec 2003 | - | -$1.50 M(+44.9%) | -$5.36 M(+11.9%) |
| Sep 2003 | - | -$1.04 M(-31.7%) | -$4.79 M(-1.8%) |
| Jun 2003 | -$5.05 M(+40.4%) | -$1.52 M(+16.4%) | -$4.87 M(+8.7%) |
| Mar 2003 | - | -$1.30 M(+40.1%) | -$4.48 M(+10.4%) |
| Dec 2002 | - | -$929.80 K(-17.1%) | -$4.06 M(+6.9%) |
| Sep 2002 | - | -$1.12 M(-0.6%) | -$3.80 M(+5.3%) |
| Jun 2002 | -$3.60 M(+38.6%) | -$1.13 M(+28.4%) | -$3.61 M(-29.7%) |
| Mar 2002 | - | -$879.00 K(+31.4%) | -$5.13 M(+20.7%) |
| Dec 2001 | - | -$668.70 K(-28.1%) | -$4.25 M(+3.1%) |
| Sep 2001 | - | -$929.50 K(-64.9%) | -$4.12 M(+29.2%) |
| Jun 2001 | -$2.59 M(+66.9%) | -$2.65 M(<-9900.0%) | -$3.19 M(+490.8%) |
| Mar 2001 | - | $0.00(-100.0%) | -$539.70 K(0.0%) |
| Dec 2000 | - | -$539.70 K(<-9900.0%) | -$539.70 K(<-9900.0%) |
| Sep 2000 | - | $0.00 | $0.00 |
| Jun 2000 | -$1.55 M | - | - |
FAQ
- What is Fennec Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals annual EBITDA year-on-year change?
- What is Fennec Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Fennec Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals TTM EBITDA year-on-year change?
What is Fennec Pharmaceuticals annual EBITDA?
The current annual EBITDA of FENC is -$12.36 M
What is the all time high annual EBITDA for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high annual EBITDA is $4.68 M
What is Fennec Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, FENC annual EBITDA has changed by +$10.22 M (+45.26%)
What is Fennec Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of FENC is -$4.68 M
What is the all time high quarterly EBITDA for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high quarterly EBITDA is $14.59 M
What is Fennec Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, FENC quarterly EBITDA has changed by -$202.00 K (-4.51%)
What is Fennec Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of FENC is $3.73 M
What is the all time high TTM EBITDA for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high TTM EBITDA is $8.57 M
What is Fennec Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, FENC TTM EBITDA has changed by -$3.75 M (-50.11%)